atheronova_sc13da-050511.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
SCHEDULE 13D/A
 
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
 
AtheroNova Inc.

(Name of Issuer)
 
Common Stock, par value $0.0001 per share

(Title of Class of Securities)
 
047438 205

(CUSIP Number)
 
Thomas W. Gardner
c/o AtheroNova Inc.
2301 Dupont Drive, Suite 525
Irvine, California 92612
(949) 476-1100

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
 
May 5, 2011

(Date of Event which Requires Filing of this Statement)
 
If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box ¨ .
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.
_____________________
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
 
Page 1 of 4

 
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
CUSIP No.  047438 205
 
Page     2       of     4   
 
1
NAME OF REPORTING PERSON
SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
 
Thomas W. Gardner
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*    (a) ¨  (b) þ
 
3
SEC USE ONLY
 
4
SOURCE OF FUNDS*
 
PF
5
CHECK BOX OF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
 
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States of America
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER
 
3,261,394
8
SHARED VOTING POWER
 
9
SOLE DISPOSITIVE POWER
 
3,261,394
10
SHARED DISPOSITIVE POWER
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
3,261,394
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* ¨
 
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
13.5% (1)
14
TYPE OF REPORTING PERSON*
 
IN
 
(1)           Based on a total of 24,219,037 shares of the Company’s common stock outstanding as of May 5, 2011.
 
 
Page 2 of 4

 
 
This Schedule 13D/A (“Schedule 13D/A”) amends the following sections of the Schedule 13D filed with the Securities and Exchange Commission on May 24, 2010 and amended on June 28, 2010 (“Schedule 13D”).
 
Item 3.  Source and Amount of Funds or Other Consideration.
 
Item 3 of Schedule 13D is supplemented and amended by the information below.
 
On May 5, 2011, the Reporting Person purchased from the Company 79,500 units at a per unit price of $0.55.  Each unit consisted of one share of Common Stock and a warrant to purchase 0.3 of a share of Common Stock.
 
Item 5.  Interest in Securities of the Issuer.
 
Item 5 of Schedule 13D is supplemented and amended by the information below.
 
Reference is made to the disclosure set forth under Item 3 this Schedule 13D/A, which disclosure is incorporated herein by reference.
 
As of May 5, 2011, the Reporting Person beneficially owned 3,237,544 shares of Common Stock, and had the right to acquire 23,850 shares of Common Stock pursuant to the exercise of a warrant acquired on May 5, 2011 (the “Shares”).  Since 24,219,037 shares of Common Stock were outstanding as of May 5, 2011, the Shares constitute approximately 13.5% of the shares of Common Stock issued and outstanding.
 
The Reporting Person has the sole power to vote or direct the vote of, and to dispose of or direct the disposition of, the Shares.
 
Transactions by the Reporting Person in Common Stock effected in the past 60 days are described in Item 3 above.
 
 
Page 3 of 4

 
 
SIGNATURE
 
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this Schedule 13D/A is true, complete and correct.
 
Dated: May 11, 2011 
 
/s/ Thomas W. Gardner  
   
Thomas W. Gardner
 
       
       

 
 
 
 
Page 4 of 4